Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie’s pipeline and R&D capabilities
AbbVie announced that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.
Nimble’s lead asset is an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis. Additionally, Nimble’s peptide synthesis, screening, and optimization platform uses proprietary technology to help drive rapid discovery and optimization of oral peptide candidates for a range of targets.
Also Read: Petauri Names Mark Levonyak EVP, New Business
“With the acquisition now complete, we are excited to expand our immunology pipeline to include Nimble’s novel oral peptide assets and look forward to integrating this proprietary technology into our R&D capabilities,” said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. “We are pleased to welcome the talented team at Nimble who share our commitment to elevating the standard of care for people living with autoimmune diseases.”
AbbVie‘s mission is to discover and deliver innovative medicines and solutions that solve serious health issues now and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.
Source: PRNewswire